Showing Latest Articles
Imatinib Sensitivity in BCR-ABL1–Positive Chronic Myeloid Leukemia Cells Is Regulated by the Remaining Normal ABL1 Allele
Cancer Research, 08/29/2011
Virgili A et al. – The intracellular concentration of imatinib and expression of its transporters were not affected, although proteins involved in BCR–ABL1 degradation were downregulated in Abl1–/– cells. Furthermore, 12 genes associated with imatinib resistance were favorably deregulated in Abl1–/– leukemia. Results indicate that loss of the normal ABL1 kinase may serve as a key prognostic factor that exerts major impact on Chronic Myeloid Leukemia(CML) treatment outcomes.